Business Context and Reporting Period
This Form 8-K Current Report was filed by Harvard Bioscience, Inc. on May 1, 2007. The filing discloses the adoption of two new executive compensation plans by the Compensation Committee of the Board of Directors effective May 1, 2007.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the company. The document focuses exclusively on the structure of new bonus plans rather than reporting period financial results.
Material Changes
The primary material change reported is the establishment of the following compensation arrangements:
- Harvard Bioscience, Inc. 2007 Corporate Bonus Plan: Provides cash bonuses to specific executives if the company achieves non-GAAP adjusted earnings per diluted share from continuing operations for the year ended December 31, 2007, in excess of a specified target.
- Harvard Apparatus 2007 Bonus Plan: Provides cash bonuses to employees of the Harvard Apparatus business unit if the unit achieves adjusted operating income for the year ended December 31, 2007, in excess of a specified target.
Guidance, Outlook, and Management Commentary
The filing outlines the mechanics of the bonus pools rather than providing forward-looking financial guidance:
- Corporate Bonus Pool: If the earnings target is surpassed, the pool will equal one-third of the non-GAAP adjusted operating income in excess of the minimum required to hit the target. The Compensation Committee retains sole discretion to adjust bonus sizes.
- Harvard Apparatus Bonus Pool: If the operating income target is surpassed, the pool will equal one-half of the excess adjusted operating income.
- Executive Participation:
- Chane Graziano (CEO): 40.7% participation percentage.
- David Green (President): 33.6% participation percentage.
- Bryce A. Chicoyne (CFO): 11.7% participation percentage.
- Susan M. Luscinski (COO): 14.0% participation percentage.
- Harvard Apparatus President: Mark A. Norige has a maximum bonus of $60,000, which may be increased to $100,000 at the company's discretion based on performance.
Risks and Contingencies: Bonuses are contingent on achieving specific non-GAAP financial targets. If targets are not met, no bonuses will be paid unless the Compensation Committee determines otherwise. Participation percentages are subject to change based on the addition or removal of plan participants.
Investor Verification Checklist
- Verify the specific non-GAAP adjusted earnings per diluted share target for the 2007 fiscal year.
- Verify the specific adjusted operating income target for the Harvard Apparatus business unit for 2007.
- Review the full text of the Harvard Bioscience, Inc. 2007 Corporate Bonus Plan (Exhibit 99.1) for detailed eligibility criteria.
- Monitor future filings for actual 2007 financial results to determine if bonus thresholds were met.